In order to meet the growing global demand for gene, cell and RNA therapies, Flash Therapeutics, a contract development and manufacturing organization (CDMO), is accelerating the ramp-up of its biomanufacturing capabilities. This will allow it to position itself for the production of large-scale clinical batches, including both integrative DNA and RNA technologies—proprietary LentiFlash technology.   This ambition requires an overall investment of around €15 million to ensure the growth of its p...